AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30132011 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise
Number of subjects: 165
Study 30132011 — intervention group
Group type: COMPARATOR
Intervention: Prescribed physical activity intervention
Number of subjects: 165
Study 27362929 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB)
Number of subjects: 30
Study 27362929 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 24347440 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 50
Study 24107896 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation for stroke patients
Number of subjects: 60
Study 24107896 — intervention group
Group type: COMPARATOR
Intervention: Healthy people (control group)
Number of subjects: 60
Study 20339958 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐NitroG and 8‐OHdG expression in NPC patients
Number of subjects: 59
Study 20339958 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 8‐OHdG levels in NPC patients
Number of subjects: 59
Study 19034247 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming device (BairHugger 505 and Upper Body Blanket 522)
Number of subjects: 6
Study 19034247 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive heating device (Geratherm Adult system)
Number of subjects: 6
Study 17165297 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-step bonding system (Excite DSC)
Number of subjects: 39
Study 17165297 — intervention group
Group type: COMPARATOR
Intervention: 3-step adhesive (Syntac)
Number of subjects: 39
Study 14581709 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft silicone dressing
Number of subjects: 38
Study 14581709 — intervention group
Group type: COMPARATOR
Intervention: Hydropolymer dressing
Number of subjects: 38
Study 10690822 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.01% mitomycin-C eye drops (n = 17)
Number of subjects: 26
Study 10690822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 26
Study 9302957 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based coronary heart disease health promotion project
Number of subjects: 0
Study 8243490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 200 mg every 12 h for 7 days
Number of subjects: 10
Study 8243490 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 500 mg every 8 h for 7 days
Number of subjects: 10
Study 3905411 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptylinoxide
Number of subjects: 57
Study 3905411 — intervention group
Group type: COMPARATOR
Intervention: trazodone
Number of subjects: 57
Study 31108180 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO treatment algorithm
Number of subjects: 88
Study 31108180 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based management
Number of subjects: 88
Study 31108180 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO alone
Number of subjects: 88
Study 26393814 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT)
Number of subjects: 65
Study 26393814 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic Plyometric Training (APT)
Number of subjects: 65
Study 26393814 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 65
Study 26586093 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with capecitabine and thalidomide after RFA
Number of subjects: 50
Study 26586093 — intervention group
Group type: COMPARATOR
Intervention: RFA only
Number of subjects: 50
Study 27036656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tat Oyi vaccine (33 µg)
Number of subjects: 48
Study 27036656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tat Oyi vaccine (11 µg)
Number of subjects: 48
Study 27036656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tat Oyi vaccine (99 µg)
Number of subjects: 48
Study 27036656 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 µg Tat Oyi)
Number of subjects: 48
Study 22458392 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (440 mg/day)
Number of subjects: 40
Study 22458392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19521723 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial chemotherapy for breast cancer
Number of subjects: 0
Study 18315512 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise (30-minute classes, five times a week for 8 weeks)
Number of subjects: 28
Study 18315512 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study 16011670 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 receptor antagonists (H1RA)
Number of subjects: 2366
Study 16011670 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 receptor antagonists (H2RA)
Number of subjects: 2366
Study 12094340 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/carboplatin
Number of subjects: 332
Study 12094340 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 332
Study 10367259 — intervention group
Group type: EXPERIMENTAL
Intervention: 740 mg/m2 amifostine administered before chemotherapy
Number of subjects: 27
Study 10367259 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amifostine)
Number of subjects: 27
Study 10367259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received 2.6 g/m2 5-fluorouracil and 500 mg/m2 folinic acid per week for 6 weeks
Number of subjects: 27
Study 7586593 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of methimazole per day
Number of subjects: 509
Study 7586593 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of methimazole per day
Number of subjects: 509
Study 1934382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg over 30 minutes followed by 1 mg.kg‐1.hr‐1 for 12 hours)
Number of subjects: 163
Study 1934382 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 micrograms/kg over 20 minutes after protamine infusion)
Number of subjects: 163
Study 1934382 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tranexamic acid and desmopressin
Number of subjects: 163
Study 1934382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 6502335 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment
Number of subjects: 467
Study 6502335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 467
Study 30876451 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunting (chronic undernutrition)
Number of subjects: 378
Study 30876451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition interventions targeting rural areas
Number of subjects: 378
Study 30592459 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cell pneumococcal vaccine (WCV)
Number of subjects: 35
Study 25727449 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction
Number of subjects: 15
Study 25727449 — intervention group
Group type: COMPARATOR
Intervention: One-on-one tutoring
Number of subjects: 15
Study 24534139 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Internet treatment
Number of subjects: 825
Study 24534139 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy and website logins
Number of subjects: 825
Study 24534139 — intervention group
Group type: EXPERIMENTAL
Intervention: Latency to TQD
Number of subjects: 825
Study 22367657 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (500-2000 g/d)
Number of subjects: 46
Study 22367657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 20733097 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT plus ICD
Number of subjects: 1820
Study 20733097 — intervention group
Group type: COMPARATOR
Intervention: ICD only
Number of subjects: 1820
Study 17685090 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin supplementation (2 capsules of 4 mg daily)
Number of subjects: 0
Study 17685090 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 identical-looking capsules)
Number of subjects: 0
Study 17348558 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-adjusted edgewise appliance
Number of subjects: 0
Study 17348558 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15246795 — intervention group
Group type: EXPERIMENTAL
Intervention: New extrication technique
Number of subjects: 12
Study 15246795 — intervention group
Group type: COMPARATOR
Intervention: Standard extrication technique
Number of subjects: 12
Study 10626717 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric 9.75 mg bupivacaine
Number of subjects: 60
Study 10626717 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric 9.75 mg bupivacaine
Number of subjects: 60
Study 10626717 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injections of 3 ml lidocaine 2%
Number of subjects: 60
Study 9369106 — intervention group
Group type: EXPERIMENTAL
Intervention: Local glyceryl trinitrate
Number of subjects: 24
Study 9369106 — intervention group
Group type: COMPARATOR
Intervention: Sphincterotomy
Number of subjects: 24
Study 1384150 — intervention group
Group type: EXPERIMENTAL
Intervention: Functioning activation rehabilitation
Number of subjects: 0
Study 1384150 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa resort rehabilitation
Number of subjects: 0
Study 1384150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis technique for psychological profiles
Number of subjects: 0
Study 3985903 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 8
Study 3985903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3985903 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow cooling
Number of subjects: 8
Study 31870938 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Number of subjects: 35
Study 31870938 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 35
Study 30604407 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration Biopsy (FNAB)
Number of subjects: 19
Study 30604407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tru-Cut Core Biopsy
Number of subjects: 19
Study 30604407 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy complications
Number of subjects: 19
Study 28456902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal ctDCS
Number of subjects: 15
Study 25966452 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to subsidized bed nets
Number of subjects: 516
Study 25966452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to subsidized bed nets)
Number of subjects: 516
Study 23444228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg plus gp100 vaccine
Number of subjects: 676
Study 23444228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg plus placebo
Number of subjects: 676
Study 23444228 — intervention group
Group type: COMPARATOR
Intervention: gp100 vaccine alone
Number of subjects: 676
Study 21527171 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (energy and protein enriched diet, oral nutritional support, calcium‐vitamin D supplement, telephone counseling by a dietitian) for 3 months postdischarge
Number of subjects: 210
Study 21527171 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 210
Study 21527171 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210
Study 18316115 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based brisk walking program (12 weeks, expending at least 300 kcal each walk)
Number of subjects: 67
Study 17001943 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg Club model (n=28)
Number of subjects: 56
Study 14527570 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0
Study 11885181 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated implants
Number of subjects: 0
Study 11885181 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-coated implants
Number of subjects: 0
Study 11885181 — intervention group
Group type: EXPERIMENTAL
Intervention: All implants in bone qualities 1 and 2 (BQ-1 and BQ-2)
Number of subjects: 0
Study 11885181 — intervention group
Group type: EXPERIMENTAL
Intervention: All implants in bone qualities 3 and 4 (BQ-3 and BQ-4)
Number of subjects: 0
Study 11885181 — intervention group
Group type: EXPERIMENTAL
Intervention: PTVs at uncovering
Number of subjects: 0
Study 11885181 — intervention group
Group type: EXPERIMENTAL
Intervention: PTVs fluctuation during routine healing and loading
Number of subjects: 0
Study 11885181 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical PTV
Number of subjects: 0
Study 8797220 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 28
Study 8797220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 1396838 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy with warfarin (n = 102)
Number of subjects: 232
Study 1396838 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole and aspirin (n = 130)
Number of subjects: 232
Study 4040486 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 5
Study 4040486 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 5
Study 30624278 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electroencephalography
Number of subjects: 152
Study 30624278 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electroencephalography background features
Number of subjects: 152
Study 29275333 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (24 mg/m2 for patients <13 years, 40 mg for others) administered subcutaneously every other week.
Number of subjects: 31
Study 29275333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 28008239 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training group performing two sessions/week (RT2, n=8)
Number of subjects: 24
Study 28008239 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training group performing three sessions/week (RT3, n=8)
Number of subjects: 24
Study 28008239 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n=8)
Number of subjects: 24
Study 23993735 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 0.2 ng/ml
Number of subjects: 80
Study 23993735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.4 ng/ml
Number of subjects: 80
Study 23993735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.5 ng/ml
Number of subjects: 80
Study 23993735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil for wound management
Number of subjects: 80
Study 23993735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil for uncovering inner layer dressings
Number of subjects: 80
Study 23993735 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 80
Study 22607233 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin-containing 4-month regimen
Number of subjects: 0
Study 22607233 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20883738 — intervention group
Group type: COMPARATOR
Intervention: DTaP 0.2 ml
Number of subjects: 551
Study 20883738 — intervention group
Group type: COMPARATOR
Intervention: DTaP 0.5 ml
Number of subjects: 551
Study 20883738 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP 0.2 ml and DTaP 0.5 ml
Number of subjects: 551
Study 17653013 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone treatment (900 mg/day intravenously for the first 2 days, then 600 mg/day)
Number of subjects: 111
Study 17653013 — intervention group
Group type: COMPARATOR
Intervention: Nontreated group
Number of subjects: 111
Study 14698516 — intervention group
Group type: EXPERIMENTAL
Intervention: Neem (Azadirachta indica) leaf extract dental gel (25 mg/g)
Number of subjects: 0
Study 14698516 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate mouthwash (0.2% w/v)
Number of subjects: 0
Study 11696124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus low-dose ondansetron (50 microg.kg(‐1) ondansetron i.v.)
Number of subjects: 193
Study 11696124 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone (placebo)
Number of subjects: 193
Study 9263718 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive diagnosis and conservative treatment
Number of subjects: 0
Study 9263718 — intervention group
Group type: EXPERIMENTAL
Intervention: Further large-scale studies
Number of subjects: 0
Study 8427724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (16 mg) orally three times daily starting 24 hours after cisplatin
Number of subjects: 50
Study 8427724 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally three times daily starting 24 hours after cisplatin
Number of subjects: 50
Study 8427724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (16 mg)
Number of subjects: 50
Study 8427724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3319537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OCBZ)
Number of subjects: 48
Study 3319537 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 48
Study 30097902 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation maps‐based (CM™) education
Number of subjects: 90
Study 30097902 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual education (IE)
Number of subjects: 90
Study 30097902 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 90
Study 29351295 — intervention group
Group type: EXPERIMENTAL
Intervention: Embrace
Number of subjects: 1456
Study 29351295 — intervention group
Group type: COMPARATOR
Intervention: CAU
Number of subjects: 1456
Study 27743903 — intervention group
Group type: EXPERIMENTAL
Intervention: rexlemestrocel-L 150×10^6
Number of subjects: 30
Study 27743903 — intervention group
Group type: EXPERIMENTAL
Intervention: rexlemestrocel-L 300×10^6
Number of subjects: 30
Study 27743903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24815499 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Watchers LITE
Number of subjects: 602
Study 24815499 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Watchers PLUS
Number of subjects: 602
Study 24815499 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 602
Study 21996146 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel therapy (loading dose 60 mg; maintenance dose 5 mg/day for patients ≥75 years old or ≤60 kg; 10 mg/day for others)
Number of subjects: 298
Study 21996146 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel therapy
Number of subjects: 298
Study 20810472 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused intervention
Number of subjects: 146
Study 20810472 — intervention group
Group type: COMPARATOR
Intervention: Monitoring-only condition
Number of subjects: 146
Study 17936422 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical technique
Number of subjects: 0
Study 17936422 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgical technique
Number of subjects: 0
Study 17936422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 0
Study 16294652 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for depressive symptoms using the PHQ-9
Number of subjects: 51
Study 16294652 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 51
Study 16294652 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management with medication or referral to a mental health specialist
Number of subjects: 51
Study 12450703 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine
Number of subjects: 240
Study 12450703 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR/V vaccine
Number of subjects: 240
Study 12450703 — intervention group
Group type: COMPARATOR
Intervention: MMR vaccine
Number of subjects: 240
Study 10475656 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove perforation indication system
Number of subjects: 113
Study 10475656 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical glove
Number of subjects: 113
Study 10475656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held mandibular fractures
Number of subjects: 113
Study 10475656 — intervention group
Group type: COMPARATOR
Intervention: Temporary intermaxillary fixation
Number of subjects: 113
Study 8734231 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine, 0.6 mL.kg‐1 intraperitoneally
Number of subjects: 24
Study 8734231 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 24
Study 1721980 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25-50 mg once daily)
Number of subjects: 201
Study 1721980 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) (25-50 mg once daily)
Number of subjects: 201
Study 1721980 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 201
Study 1721980 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 201
Study 31126570 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinium arctostaphylos berry extract (400 mg capsule, three times daily for 3 months)
Number of subjects: 50
Study 31126570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27755056 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscope-assisted lightwand technique (group L, n = 82)
Number of subjects: 162
Study 27755056 — intervention group
Group type: COMPARATOR
Intervention: Conventional lightwand technique (group C, n = 80)
Number of subjects: 162
Study 26018581 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient double-balloon catheter cervical ripening (n = 33)
Number of subjects: 48
Study 26018581 — intervention group
Group type: COMPARATOR
Intervention: Inpatient double-balloon catheter cervical ripening (n = 15)
Number of subjects: 48
Study 26018581 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (outpatient and inpatient)
Number of subjects: 48
Study 26018581 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives and doctors (n = 90)
Number of subjects: 48